Statement on Behalf of Jennifer Hawks Bland on ORPHAN Cures Act

Statement on Behalf of Jennifer Hawks Bland, CEO of NewYorkBIO 

"At this pivotal moment in our industry, NewYorkBIO is pleased to see the ORPHAN Cures Act included in the Senate passed version of H.R. 1, the One Big Beautiful Bill Act. This important legislation will improve the lives of those with rare diseases and strengthen the United States’ leadership in global biotech. The ORPHAN Cures Act will drive industry growth and support the development of life-saving treatments, especially in the wake of the Inflation Reduction Act, and its effect on rare disease therapies.  NewYorkBIO urges the House to retain this critical legislation as it takes up consideration of the latest version of H.R. 1.   

As the leading advocate for New York’s life science community, NewYorkBIO supports the ORPHAN Cures Act and its mission to incentivize research and innovation for rare conditions. ultimately improving health outcomes for patients in New York and around the world."